Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial

Journal of the Formosan Medical Association = Taiwan Yi Zhi
Charles Lung-Cheng HuangHai-Gwo Hwu

Abstract

To compare the efficacy and safety profile between intramuscular (IM) olanzapine and IM haloperidol plus IM lorazepam in acute schizophrenic patients with moderate to severe agitation. This was a prospective, randomized, open-label study. Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30). Agitation was measured with Positive and Negative Syndrome Scale Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES) during the first 2 hours and at 24 hours after the first injection. Safety was assessed using the Simpson-Angus Scale and Barnes Akathisia Rating Scale and by recording adverse events at 24 hours following the first injection. The Clinical Global Impression-Severity scale was also rated. The PANSS-EC scores decreased significantly at 2 hours after the first injection in both groups (olanzapine: -10.2, p < 0.001; haloperidol + lorazepam: -9.9, p < 0.001). Haloperidol plus lorazepam was not inferior to olanzapine in reducing agitation at 2 hours. There were no significant differences in PANSS-EC or ACES scores between the two groups within 2 hours following the first...Continue Reading

References

Jan 1, 1990·Schizophrenia Bulletin·S R Kay, S Sevy
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Nov 30, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·R L Binder, D E McNiel
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karena M MeehanAlan Breier
Apr 12, 2002·CNS Drugs·Glenn W Currier, Adam Trenton
Jul 2, 2003·Emergency Medicine Journal : EMJ·A YildizA Turgay
Feb 6, 2004·General Hospital Psychiatry·Michael H Allen, Glenn W Currier
Apr 22, 2004·Schizophrenia Research·Jean-Pierre LindenmayerVirginia L Stauffer
Nov 4, 2004·The Annals of Pharmacotherapy·Karen J Tulloch, Peter J Zed
May 27, 2005·Drugs·John Battaglia
May 4, 2011·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Leonardo BaldaçaraAndrea Parolin Jackoswski
Jun 5, 2012·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Chen-Chung LiuWei J Chen

❮ Previous
Next ❯

Citations

Jan 8, 2020·Basic & Clinical Pharmacology & Toxicology·Lone Baandrup
Feb 6, 2019·European Psychiatry : the Journal of the Association of European Psychiatrists·Maarten BakGeert Dom
Sep 4, 2018·Neuropsychopharmacology Reports·Kotaro HattaUNKNOWN JAST study group
Mar 12, 2021·Frontiers in Psychiatry·Mario AmoreAndrea Fagiolini
Jul 16, 2021·The American Journal of Emergency Medicine·Richard ChildersGary M Vilke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.